Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
O. Sartor, J. de Bono, K.N. Chi, K. Fizazi, K. Herrmann, K. Rahbar, S.T. Tagawa, L.T. Nordquist, N. Vaishampayan, G. El‑Haddad, C.H. Park, T.M. Beer, A. Armour, W.J. Pérez‑Contreras, M. DeSilvio, E. Kpamegan, G. Gericke, R.A. Messmann, M.J. Morris, and B.Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 ( 177 Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Категорії:
Видавництво:
The New England Journal of Medicine
Мова:
english
Сторінки:
13
Файл:
PDF, 184 KB
IPFS:
,
english0